DexCom, Inc. (DXCM)
66.37
-0.69
(-1.03%)
USD |
NASDAQ |
Dec 31, 16:00
66.49
+0.12
(+0.18%)
After-Hours: 20:00
DexCom Cash from Investing (Quarterly): 192.80M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Abbott Laboratories | -457.00M |
| BioLife Solutions, Inc. | -5.967M |
| Krystal Biotech, Inc. | -4.286M |
| Boston Scientific Corp. | -502.00M |
| Tandem Diabetes Care, Inc. | 20.54M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 659.90M |
| Cash from Financing (Quarterly) | -175.00M |
| Free Cash Flow | 1.062B |
| Free Cash Flow Per Share (Quarterly) | 1.422 |
| Free Cash Flow to Equity (Quarterly) | 583.10M |
| Free Cash Flow to Firm (Quarterly) | 583.19M |
| Free Cash Flow Yield | 3.93% |